Jump to content
PT-141 Order A gallery-wall reading of the PT-141 (bremelanotide) literature — the approved-population data hung beside the honest tolerability picture, with field reports pinned where they belong: outside the citations.
Who decides
Provider review
Where
U.S. patients only
Required
A prescription
Promise Peptides PT-141 (bremelanotide) product card at mypromise.com, marked Rx only

Promise Peptides — online at mypromise.com — currently prescribes PT-141 (bremelanotide). The medication is prescription-only.

A U.S.-licensed clinician evaluates every request. That clinician decides whether to prescribe and declines some requests.

The treatment offered also depends on the state. Compounded preparations have no approval from the FDA.

One approved use · slight help · common nausea

PT-141 gave one group a small gain

Ads cast a wide net. Good studies point to a single limited use and common nausea.

See what the studies foundRead about the main harms
An abstract forest-green editorial plate of a melanocortin MC4R receptor coil with a small ligand node docking at it, with a single hot-pink accent splash, on a deep cool near-black gallery wall

An unexpected sexual response led to a new drug

The first research team tested a medicine developed to add skin color. A sexual response appeared by surprise, so the team made PT-141 to see whether it might help patients. Early papers also called the new drug PT-141. Doctors now call the approved drug bremelanotide.

The FDA approved one limited use in June 2019. It was for women before menopause whom ongoing low desire deeply troubled [6]. Men weren't studied, nor were women past menopause. Those groups remain outside the approval.

The best studies found only a small average gain. Women wanted sex a little more and felt less upset about low desire. Over longer follow-up, about four in ten felt sick [4]. For you, that common sickness must be weighed with the limited help.

PT-141 acts on desire, not blood flow

Researchers first called bremelanotide PT-141. Chemists joined a few protein parts to make this peptide [1]. That tells you what the drug is made of, not whether it works. It copies one small piece from a hormone your body makes [1].

PDE-5 is a lab code for common erection pills that help blood reach the penis. PT-141 takes another route: it changes how parts of the brain handle desire [5]. That may matter when desire is the problem. It still doesn't mean the drug will help you.

Approved bremelanotide injection comes as a finished shot. Compounded PT-141 (bremelanotide) requires a prescription after a licensed provider reviews the request and decides; not everyone qualifies. U.S. access varies by state and treatment. Compounded medications are not FDA-approved. Powder sold as “PT-141 research chemical” belongs in a lab, not patient care [6]. Study amounts do not set your care.

PT-141 caused sexual responses in animals first

Researchers first gave PT-141 to animals [1]. Rats and monkeys had sexual responses, but animals can't show whether a patient will benefit. Human studies matter more.

After the drug, males of both species had erections. In 2003, the response grew with the amount among men having trouble with erections [1]. That early finding did not win approval for men. It remains an early finding, not proof of useful care.

Female rats sought mating more often after the drug [2]. They still moved as usual, and simple body reflexes didn't change. That result helped set up studies in women. It couldn't predict how much help a woman would feel.

The largest studies found a small gain

Two matching Phase 3 studies give the best proof. They included 1,267 women before menopause. For 24 weeks, women used 1.75 mg when needed or a placebo shot containing no drug [3]. No later large test preceded approval.

Women answered a survey on desire and distress. Question 13 asked how upset low desire made them. The paper's figure was below .001, so chance alone was an unlikely answer [3]. A 52-week study followed 684 women: the small gain lasted, while the same known harms remained and no different harm appeared [4].

A marketing page may call that success. Other experts asked whether most women would notice the average change [8]. They accepted that a gain existed but judged it small. That's the fairer reading.

A 2022 scan study included 31 women troubled by low desire. Desire scores stayed higher for up to 24 hours after the drug [5]. Areas that judge sexual sights and body feelings also worked differently. The scan doesn't turn PT-141 into a strong treatment.

Approval covers only one group

FDA approval covers one narrow group. On June 21, 2019, bremelanotide was approved only for women with HSDD who have not reached menopause [6]. Here, HSDD describes low desire that lasts and leaves a woman deeply upset. The approval leaves out men, women past menopause, erection trouble, and broad performance claims [6].

A 2003 study found a response among men unable to get a firm erection [1]. A 2024 clinic note described men who received the drug for a use the FDA hadn't approved [12]. Neither report proves the drug helps men. Both are early signs that still need a fair test.

The harm isn't minor for everyone. Nausea is common, and blood pressure may briefly climb. FDA instructions rule out use for certain patients with uncontrolled pressure or diseased blood vessels [4][6]. Frequent use may leave some skin and gums darker.

Read who the approval covers and the main harms first. Common questions gives short answers. Full references name the papers behind each study claim. Use these pages to shape plain questions for your doctor.

User stories can't show your chance of harm

Open Cautions & Reports for stories from people using lab material. No study compared those stories with a placebo group. They can't show your chance of help or harm, so the proven warnings matter more.